Core Insights - ARS Pharmaceuticals will present significant real-world data on the effectiveness of neffy® (epinephrine nasal spray) at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology, showcasing its impact on treating anaphylaxis [1][2] Group 1: Presentation Details - One late-breaking oral presentation titled "Real World Data on the Effectiveness of Epinephrine Nasal Spray in Clinical Practice – Update" will be delivered on November 8, 2025 [3] - Six poster presentations will cover various aspects of neffy, including its effectiveness compared to autoinjectors, patient surveys, and case reports from clinical settings [5][6] Group 2: Expert Opinions - Dr. Jonathan Spergel emphasized that the real-world data supports intranasal epinephrine as a reliable alternative to injections, providing confidence to clinicians and patients [2] - Sarina Tanimoto, Co-founder and Chief Medical Officer of ARS Pharma, highlighted the breadth of research reinforcing the value of neffy in allergic emergencies [2] Group 3: Product Information - Neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in patients aged 4 years and older who weigh at least 33 lbs [8] - The product aims to address limitations associated with traditional epinephrine auto-injectors, such as needle fear and portability issues [17]

Core Insights - ARS Pharmaceuticals is presenting real-world data on the effectiveness of neffy® (epinephrine nasal spray) at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology, highlighting that approximately 90% of patients experiencing anaphylaxis were effectively treated with a single dose of neffy [1][2] - The presentations include one late-breaking oral presentation and six poster presentations, showcasing the treatment's value and effectiveness in various clinical settings [1][2] Company Overview - ARS Pharmaceuticals is focused on empowering at-risk patients and their caregivers to manage severe allergic reactions that could lead to anaphylaxis [1][18] - The company is commercializing neffy®, an epinephrine nasal spray indicated for emergency treatment of Type I allergic reactions, including anaphylaxis, in patients aged 4 years and older [1][18] Presentation Details - The oral presentation titled "Real World Data on the Effectiveness of Epinephrine Nasal Spray in Clinical Practice – Update" will take place on November 8, 2025 [3] - Six poster presentations will cover various topics, including the effectiveness of neffy in clinical settings and patient experiences with the nasal spray compared to autoinjectors [5][6][7] Clinical Evidence - Dr. Jonathan Spergel emphasized that the consistency of outcomes across diverse patient populations supports the reliability of intranasal epinephrine, asserting that it is as effective as injections [2] - Case reports presented during the meeting demonstrate the successful use of neffy in patients undergoing oral food challenges and allergy immunotherapy [2][7] Market Context - There are approximately 40 million people in the U.S. experiencing Type I allergic reactions, with a significant number diagnosed with severe reactions that may lead to anaphylaxis [17] - Despite the availability of epinephrine auto-injectors, many patients delay or do not administer treatment during emergencies due to various limitations, highlighting the need for alternatives like neffy [17]